Israel “Izzy” Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesn’t?
You don’t become one of the world’s wealthiest hedge fund managers by making ill-advised investing decisions. And make no mistake about it: Israel “Izzy” Englander ranks among the world’s wealthiest hedge fund managers, with a net worth of roughly $25.8 billion.
The billionaire increased his Millennium Management hedge fund’s position in Bristol Myers Squibb (NYSE: BMY) by a whopping 780% in the first quarter of 2026. However, analysts aren’t nearly as bullish about the pharma stock. Does Englander know something about Bristol Myers Squibb that Wall Street doesn’t?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
What Englander probably likes about Bristol
It’s easy for investors to focus on Bristol Myers Squibb’s looming patent cliff. The company’s top-selling drug, blood thinner Eliquis, loses U.S. patent exclusivity in 2028. Sales are already sinking for several other products that have previously lost patent protection, including blood cancer drugs Revlimid and Pomalyst.
So what does Englander like about Bristol Myers Squibb? We can make an educated guess.
For one thing, the hedge fund manager probably appreciates that the drugmaker’s growth portfolio now makes up more than half of its total revenue. Newer products such as cancer therapy Breyanza and heart failure drug Camzyos have especially strong momentum.
Englander likely views Bristol Myers Squibb’s pipeline favorably as well. The company awaits U.S. Food and Drug Administration (FDA) approvals for iberdomide by Aug. 17, 2026, and for mezigdomide by May 13, 2027. Both drugs target relapsed or refractory multiple myeloma. Bristol Myers Squibb also expects to report results from numerous pivotal clinical trials over the next two years.
The billionaire almost certainly likes Bristol Myers Squibb’s forward price-to-earnings ratio of 9.6. And while Englander doesn’t usually focus on income, the big pharma company’s juicy dividend is probably a plus for the stock in his eyes.
Secret information?
But does Englander know something about Bristol Myers Squibb that Wall Street doesn’t? Probably not. All the information he likely used to decide to buy the pharma stock is also readily available to analysts.
It’s important to note as well that Millennium Management is making a relatively small bet on Bristol Myers Squibb even after the Q1 purchase. Englander can easily afford to be wrong about the stock.
